Table 2.
Soluble protein levels * in the 4 study groups: mean ± SD and ANOVA results.
| Soluble Protein | Control (n = 86) | AUD (n = 132) | HIV (n = 54) | AUD + HIV (n = 49) | ANOVA | |
|---|---|---|---|---|---|---|
| F Ratio | p-Value | |||||
| CD40L | 109.12 ± 0.41 | 109.19 ± 0.73 | 109.08 ± 0.75 | 108.97 ± 0.36 | 1.71 | 0.16 |
| EGF | 31.64 ± 0.51 | 31.52 ± 0.51 | 31.55 ± 0.86 | 31.33 ± 0.42 | 2.97 | 0.03 |
| EOTAXIN | 102.41 ± 0.55 | 102.42 ± 0.61 | 102.66 ± 0.64 | 102.48 ± 0.59 | 2.46 | 0.06 |
| FGFB | 22.07 ± 0.58 | 21.97 ± 0.46 | 21.91 ± 0.41 | 21.84 ± 0.5 | 2.43 | 0.07 |
| FLT3L | 34.14 ± 0.47 | 34.13 ± 0.41 | 34.28 ± 0.59 | 34.11 ± 0.45 | 1.67 | 0.17 |
| Fractaline | 19.61 ± 0.35 | 19.63 ± 0.32 | 19.6 ± 0.34 | 19.51 ± 0.28 | 1.49 | 0.22 |
| GCSF | 26.85 ± 0.41 | 26.74 ± 0.27 | 26.69 ± 0.31 | 26.75 ± 0.42 | 2.81 | 0.04 |
| GMCSF | 25.85 ± 0.28 | 25.81 ± 0.23 | 25.75 ± 0.20 | 25.74 ± 0.26 | 2.90 | 0.04 |
| GRO ‡ | 935.26 ± 1.02 | 935.54 ± 0.97 | 935.37 ± 1.03 | 935.29 ± 1 | 1.66 | 0.18 |
| IFNA2 | 20.8 ± 0.31 | 20.83 ± 0.41 | 20.77 ± 0.26 | 20.74 ± 0.26 | 0.94 | 0.42 |
| IFNG ‡ | 51.86 ± 1.18 | 51.64 ± 0.88 | 51.65 ± 1.01 | 51.47 ± 0.94 | 1.72 | 0.16 |
| IL1A | 30.96 ± 0.44 | 30.81 ± 0.36 | 30.81 ± 0.31 | 30.76 ± 0.24 | 4.52 | 0.004 |
| IL1B | 20.68 ± 0.52 | 20.56 ± 0.35 | 20.45 ± 0.23 | 20.41 ± 0.28 | 7.04 | 0.0001 |
| IL1RA | 30.78 ± 0.4 | 30.76 ± 0.42 | 30.81 ± 0.50 | 30.72 ± 0.44 | 0.47 | 0.70 |
| IL2 | 24.94 ± 0.51 | 24.85 ± 0.37 | 24.77 ± 0.27 | 24.74 ± 0.33 | 3.49 | 0.02 |
| IL3 | 20.04 ± 0.37 | 20.01 ± 0.24 | 19.96 ± 0.18 | 19.93 ± 0.18 | 2.06 | 0.11 |
| IL4 | 29.01 ± 0.42 | 28.95 ± 0.38 | 28.91 ± 0.35 | 28.77 ± 0.3 | 4.29 | 0.01 |
| IL5 | 19.64 ± 0.51 | 19.54 ± 0.33 | 19.59 ± 0.55 | 19.5 ± 0.35 | 1.59 | 0.19 |
| IL6 | 33.09 ± 0.62 | 33.01 ± 0.52 | 33.04 ± 0.58 | 32.86 ± 0.46 | 1.82 | 0.14 |
| IL7 | 21.05 ± 0.38 | 21 ± 0.26 | 20.96 ± 0.2 | 20.96 ± 0.29 | 1.64 | 0.18 |
| IL8 | 125.98 ± 0.61 | 125.94 ± 0.54 | 126.12 ± 0.62 | 126.07 ± 0.6 | 1.43 | 0.23 |
| IL9 | 24.86 ± 0.52 | 24.76 ± 0.4 | 24.67 ± 0.37 | 24.62 ± 0.29 | 4.17 | 0.007 |
| IL10 | 28.77 ± 0.49 | 28.72 ± 0.34 | 28.69 ± 0.36 | 28.66 ± 0.27 | 1.05 | 0.37 |
| IL12P40 ‡ | 27.13 ± 1.25 | 26.88 ± 0.93 | 26.67 ± 0.61 | 26.81 ± 0.99 | 2.67 | 0.05 |
| IL12P70 ‡ | 21.52 ± 1 | 21.51 ± 1.1 | 21.28 ± 0.71 | 21.32 ± 1 | 1.09 | 0.35 |
| IL13 | 23.74 ± 0.62 | 23.6 ± 0.47 | 23.55 ± 0.51 | 23.47 ± 0.31 | 3.54 | 0.02 |
| IL15 | 30.6 ± 0.38 | 30.55 ± 0.28 | 30.48 ± 0.18 | 30.5 ± 0.3 | 2.12 | 0.10 |
| IL17 | 44.53 ± 0.73 | 44.35 ± 0.58 | 44.4 ± 0.64 | 44.15 ± 0.59 | 3.79 | 0.01 |
| IP10 ‡ | 884.1 ± 0.83 | 884.1 ± 0.94 | 884.71 ± 0.96 | 884.97 ± 1.1 | 14.76 | <0.0001 |
| MCP1 ‡ | 966.42 ± 0.99 | 966.5 ± 1.01 | 966.71 ± 0.98 | 966.51 ± 1.01 | 0.93 | 0.43 |
| MCP3 | 29.21 ± 0.8 | 29.01 ± 0.57 | 28.95 ± 0.61 | 28.95 ± 0.62 | 2.67 | 0.05 |
| MDC ‡ | 692.47 ± 1 | 692.63 ± 0.95 | 692.54 ± 1.19 | 692.61 ± 0.92 | 0.49 | 0.69 |
| MIP1A | 97.21 ± 0.62 | 97.1 ± 0.59 | 97.19 ± 0.49 | 97.38 ± 1.1 | 2.08 | 0.10 |
| MIP1B | 58.64 ± 0.49 | 58.57 ± 0.44 | 58.6 ± 0.39 | 58.67 ± 0.67 | 0.68 | 0.56 |
| PDGFAA | 3394.5 ± 0.84 | 3394.66 ± 0.85 | 3394.63 ± 0.82 | 3394.55 ± 0.69 | 0.78 | 0.58 |
| PDGFBB | 636.33 ± 1.04 | 636.7 ± 0.89 | 636.51 ± 0.94 | 636.47 ± 0.89 | 2.78 | 0.04 |
| RANTES ‡ | 7924.63 ± 1.08 | 7924.86 ± 1.12 | 7924.95 ± 0.73 | 7924.84 ± 0.72 | 1.46 | 0.23 |
| TGFA | 27.41 ± 0.46 | 27.4 ± 0.45 | 27.46 ± 0.63 | 27.39 ± 0.52 | 0.19 | 0.91 |
| TNFA ‡ | 64.4 ± 0.89 | 64.63 ± 0.89 | 65.37 ± 1.06 | 65.08 ± 1.06 | 14.23 | <0.0001 |
| TNFB | 27.78 ± 0.61 | 27.7 ± 0.52 | 27.66 ± 0.67 | 27.56 ± 0.45 | 1.69 | 0.17 |
| VEGF | 26.83 ± 0.52 | 26.75 ± 0.42 | 26.73 ± 0.6 | 26.64 ± 0.5 | 1.56 | 0.20 |
* R-utility corrected for plate and nonspecific binding artifacts; ‡ corrected for age, sex, race or combination (see text for details); bold = significant.